KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Enterprise Value (2016 - 2026)

Emergent BioSolutions has reported Enterprise Value over the past 17 years, most recently at -$161.5 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 5.69% year-over-year to -$161.5 million; the TTM value through Mar 2026 reached -$161.5 million, down 5.69%, while the annual FY2025 figure was -$209.1 million, 98.01% down from the prior year.
  • Enterprise Value for Q1 2026 was -$161.5 million at Emergent BioSolutions, up from -$209.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$71.0 million in Q2 2024 and troughed at -$642.6 million in Q4 2022.
  • A 5-year average of -$226.6 million and a median of -$161.5 million in 2026 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 82.62% in 2023 and later crashed 281.69% in 2025.
  • Year by year, Enterprise Value stood at -$642.6 million in 2022, then surged by 82.62% to -$111.7 million in 2023, then grew by 5.46% to -$105.6 million in 2024, then tumbled by 98.01% to -$209.1 million in 2025, then grew by 22.76% to -$161.5 million in 2026.
  • Business Quant data shows Enterprise Value for EBS at -$161.5 million in Q1 2026, -$209.1 million in Q4 2025, and -$249.2 million in Q3 2025.